Calpain-mediated truncation of GSK-3 in post-mortem brain samples

Journal of Neuroscience Research

Volumn 87, Issue 5, 2009, Pages 1156-1161

  Goñi Oliver, Paloma ^a   Avila, Jesús ^a,b   Hernández, Félix ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Calpain; GSK 3; Post mortem

Indexed keywords

[1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; CALCIUM; CALPAIN; CALPEPTIN; GLYCOGEN SYNTHASE KINASE 3; PROTEIN P35; SPECTRIN;

ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CADAVER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN QUATERNARY STRUCTURE;

AGED; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; CALPAIN; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; POSTMORTEM CHANGES;

EID: 65949119740     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21932     Document Type: Article

References (28)

1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. 1997. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797-3804.
2. Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han D, Lin R, Paudel HK. 2003. 14-3-3 Connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J Biol Chem 278:12722-12728.
3. Araujo IM, Gil JM, Carreira BP, Mohapel P, Petersen A, Pinheiro PS, Soulet D, Bahr BA, Brundin P, Carvalho CM. 2008. Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus. J Neurochem 105:666-676.
4. Avila J, Hernández F. 2007. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7:1527-1533.
5. Camins A, Verdaguer E, Folch J, Pallas M. 2006. Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12:135-148.
6. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769-776.
7. Czogalla A, Sikorski AF. 2005. Spectrin and calpain: a "target" and a "sniper" in the pathology of neuronal cells. Cell Mol Life Sci 62:1913-1924.
8. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH. 2001. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105:721-732. Eldar-Finkelman H. 2002. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8:126-132.
9. Frame S, Cohen P. 2001. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359:1-16.
10. Goll DE, Thompson VF, Li H, Wei W, Cong J. 2003. The calpain system. Physiol Rev 83:731-801.
11. Goñi-Oliver P, Lucas JJ, Avila J, Hernández F. 2007. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 282:22406-22413.
12. Huang Y, Wang KK. 2001. The calpain family and human disease. Trends Mol Med 7:355-362.
13. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. 1993. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12:803-808.
14. Jiang SX, Kappler J, Zurakowski B, Desbois A, Aylsworth A, Hou ST. 2007. Calpain cleavage of collapsin response mediator proteins in ischemic mouse brain. Eur J Neurosci 26:801-809.
15. Jope RS, Johnson GV. 2004. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95-102.
16. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S. 2000. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275:17166-17172.
17. LaFerla FM. 2002. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3:862-872.
18. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. 2000. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-364.
19. Li PA, Howlett W, He QP, Miyashita H, Siddiqui M, Shuaib A. 1998. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett 247: 17-20.
20. Li X, Friedman AB, Roh MS, Jope RS. 2005. Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem 92:701-704.
21. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. 2006. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24:627-633.
22. Patrick GN, Zukerberg L, Nikolic M, delaMonte S, Dikkes P, Tsai LH. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622.
23. Saito K, Elce JS, Hamos JE, Nixon RA. 1993. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 90:2628-2632.
24. Sheppard A, Wu J, Bahr BA, Lynch G. 1991. Compartmentation and glycoprotein substrates of calpain in the developing rat brain. Synapse 9:231-234.
25. Sorimachi Y, Harada K, Yoshida K. 1996. Involvement of calpain in postmortem proteolysis in the rat brain. Forensic Sci Int 81:165-174.
26. Taniguchi S, Fujita Y, Hayashi S, Kakita A, Takahashi H, Murayama S, Saido TC, Hisanaga S, Iwatsubo T, Hasegawa M. 2001. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 489:46-50.
27. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. 2001. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 8:593-596.
28. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9:2431-2438.